Healthcare provider profile · identity verified

Hugo Twaddle, MD

Internal Medicine · BETHLEHEM, PA · NPI 1609826742

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Lisinopril	Lisinopril	562	167
Amlodipine Besylate	Amlodipine Besylate	549	161
Atorvastatin Calcium	Atorvastatin Calcium	525	156
Gabapentin	Gabapentin	340	130
Losartan Potassium	Losartan Potassium	334	98
Omeprazole	Omeprazole	326	103
Metformin Hcl	Metformin Hcl	324	94
Levothyroxine Sodium	Levothyroxine Sodium	309	91
Simvastatin	Simvastatin	243	60
Rosuvastatin Calcium	Rosuvastatin Calcium	202	62
Pantoprazole Sodium	Pantoprazole Sodium	199	53
Citalopram Hbr	Citalopram Hydrobromide	198	68
Metoprolol Succinate	Metoprolol Succinate	185	57
Duloxetine Hcl	Duloxetine Hcl	168	53
Albuterol Sulfate Hfa	Albuterol Sulfate	164	62
Metoprolol Tartrate	Metoprolol Tartrate	141	38
Eliquis	Apixaban	140	38
Alprazolam	Alprazolam	105	29
Fluticasone Propionate	Fluticasone Propionate	100	47
Glimepiride	Glimepiride	92	26
Sertraline Hcl	Sertraline Hcl	92	25
Hydrochlorothiazide	Hydrochlorothiazide	90	31
Furosemide	Furosemide	83	32
Lorazepam	Lorazepam	80	12
Pravastatin Sodium	Pravastatin Sodium	77	23
Allopurinol	Allopurinol	67	19
Jardiance	Empagliflozin	60	14
Trazodone Hcl	Trazodone Hcl	60	17
Meloxicam	Meloxicam	58	22
Tamsulosin Hcl	Tamsulosin Hcl	58	16
Escitalopram Oxalate	Escitalopram Oxalate	54	16
Famotidine	Famotidine	54	17
Atenolol	Atenolol	52	14
Ozempic	Semaglutide	51	14
Carvedilol	Carvedilol	49	17
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	48	suppressed
Buspirone Hcl	Buspirone Hcl	47	21
Azelastine Hcl	Azelastine Hcl	46	25
Doxazosin Mesylate	Doxazosin Mesylate	44	14
Montelukast Sodium	Montelukast Sodium	41	11
Synthroid	Levothyroxine Sodium	41	12
Warfarin Sodium	Warfarin Sodium	40	13
Propranolol Hcl	Propranolol Hcl	39	12
Clopidogrel	Clopidogrel Bisulfate	38	suppressed
Metformin Hcl Er	Metformin Hcl	38	14
Lidocaine	Lidocaine	36	24
Meclizine Hcl	Meclizine Hcl	35	15
Alendronate Sodium	Alendronate Sodium	34	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	33	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	32	suppressed
Tradjenta	Linagliptin	32	suppressed
Topiramate	Topiramate	31	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	31	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	30	13
Potassium Chloride	Potassium Chloride	30	suppressed
Trulicity	Dulaglutide	29	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	29	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	27	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	27	18
Enalapril Maleate	Enalapril Maleate	26	suppressed
Celecoxib	Celecoxib	25	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	25	suppressed
Mirtazapine	Mirtazapine	25	suppressed
Januvia	Sitagliptin Phosphate	24	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	24	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	22	suppressed
Nifedipine Er	Nifedipine	22	suppressed
Ondansetron Odt	Ondansetron	22	13
Xarelto	Rivaroxaban	22	suppressed
Chlorthalidone	Chlorthalidone	21	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	12
Tramadol Hcl	Tramadol Hcl	21	suppressed
Repaglinide	Repaglinide	20	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	19	12
Glipizide Er	Glipizide	19	suppressed
Methylprednisolone	Methylprednisolone	19	16
Olanzapine	Olanzapine	19	suppressed
Temazepam	Temazepam	19	suppressed
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	18	suppressed
Divalproex Sodium	Divalproex Sodium	17	suppressed
Finasteride	Finasteride	17	suppressed
Valsartan	Valsartan	17	suppressed
Breo Ellipta	Fluticasone/Vilanterol	16	suppressed
Calcitriol	Calcitriol	16	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	16	suppressed
Klor-Con M20	Potassium Chloride	16	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Benazepril Hcl	Benazepril Hcl	15	suppressed
Ibuprofen	Ibuprofen	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	13	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Mounjaro	Tirzepatide	13	suppressed
Nabumetone	Nabumetone	13	suppressed
Rizatriptan	Rizatriptan Benzoate	13	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	12	suppressed
Fenofibrate	Fenofibrate,micronized	12	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	12	suppressed
Labetalol Hcl	Labetalol Hcl	12	suppressed
Midodrine Hcl	Midodrine Hcl	12	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	11	suppressed
True Comfort Pro Alcohol Pads	Alcohol Antiseptic Pads	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error